Modular Medical, Inc. today announced the pricing of an upsized underwritten public offering of 8,816,900 shares of its common stock and warrants to purchase 4,408,450 shares of its common stock.
Modular Medical Announces Pricing of Upsized $9.4 Million Public Offering Read More »
Palatin Technologies, Inc. today announced financial results for its fiscal third quarter ended March 31, 2023.
La estratosfera es una capa bastante tranquila de la atmósfera terrestre. Raramente perturbada por aviones o turbulencias, los micrófonos en la estratosfera captan sonidos que no se oyen en ningún otro lugar, al menos de esa manera. Esto incluye sonidos naturales como truenos, s …
Shorla Oncology today announced the commercial launch of the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
MindBio Therapeutics Corp. today issued a letter to shareholders from Justin Hanka, Co-Founder and Chief Executive Officer of MindBio.
Inhibikase Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 2 ‘201’ trial evaluating IkT-148009, the Company’s novel Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.
Soligenix, Inc. announced today that the European Patent Office has granted a patent entitled “Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis”.
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis Read More »
Aviceda Therapeutics today announced the appointment of Patrick Johnson to its board of directors.
Caris Life Sciences® announced that Robert H. Lurie Comprehensive Cancer Center of Northwestern University has joined the Caris Precision Oncology Alliance™.
